Related Experiment Video
Updated: Jun 6, 2025
Transgenic Rodent Assay for Quantifying Male Germ Cell Mutant Frequency
Published on: August 6, 2014
Non-alkylating agents-induced gonadotoxicity in pre-pubertal males: Insights on the clinical and pre-clinical front
Sruthi Sriram1, Tiago Macedo1, Annelies Mavinkurve-Groothuis1
1Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Abstract:
Whilst chemotherapy regimens have proven to be more successful for pediatric cancer patients over the years, their influence on long-term side effects is relatively poorly understood. One of the possible targets is the gonads, with gonadotoxic agents representing those that threaten the patient's ability to have children post surviving the primary disease treatment. Many risk stratification guidelines have categorized these agents based on the severity of their effect on the pre-pubertal testis. While the consensus is that those agents factored with a cyclophosphamide equivalent dosage pose the highest threat to fertility (e.g. alkylating agents), other agents might still contribute to a reduced testis function; especially in the case of combination therapies. Besides, it is important to note that studies deciphering the effect of other non-alkylating agents on the pre-pubertal testis lack standardized conclusions for clinically relevant outcomes. This makes it imperative to ensure the knowledge gap is addressed between the clinic and pre-clinic to understand potential gonadotoxic effects, ultimately leading to improved patient care. Therefore, this review will summarize the key findings in understanding the gonadotoxic effects of the most commonly researched non-alkylating agents: vincristine, etoposide, doxorubicin, and imatinib on the pre-pubertal testis.
Insights
Pediatric cancer survivors face poorly understood long-term side effects from chemotherapy. This review examines the gonadotoxic effects of non-alkylating agents like vincristine on the pre-pubertal testis, aiming to improve patient care.
Area of Science:
- Pediatric Oncology
- Reproductive Toxicology
- Pharmacology
Background:
- Chemotherapy improves pediatric cancer survival but has poorly understood long-term side effects.
- Gonadotoxic agents threaten fertility in cancer survivors.
- Current guidelines focus on alkylating agents, leaving gaps in understanding other drug classes.
Purpose of the Study:
- To review the gonadotoxic effects of common non-alkylating chemotherapy agents on the pre-pubertal testis.
- To address the knowledge gap between clinical and preclinical understanding of these effects.
- To inform improved patient care strategies for pediatric cancer survivors.
Main Methods:
- Literature review of studies on vincristine, etoposide, doxorubicin, and imatinib.
- Analysis of effects on pre-pubertal testicular function.
- Synthesis of findings regarding clinical relevance and standardized outcomes.
Main Results:
- Non-alkylating agents may impact testicular function, especially in combination therapies.
- Limited standardized conclusions exist for the clinical outcomes of these agents.
- Further research is needed to clarify the specific risks associated with each agent.
Conclusions:
- Understanding the gonadotoxicity of non-alkylating agents is crucial for pediatric cancer care.
- Bridging the gap between preclinical and clinical research is essential.
- This review highlights the need for standardized outcome measures in evaluating testicular toxicity.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
01:07Teratogenicity
01:23Infertility in Males
01:41Spermatogenesis